Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Eyelid ptosis, characterized by the drooping of the upper eyelid, can significantly impair vision and aesthetics. Surgical repair is often necessary, and the choice between the anterior and posterior approaches is crucial for optimal outcomes. This review compares these two techniques based on efficacy, safety, and recovery. The anterior approach, typically involving an external incision along the eyelid crease, allows direct access to the levator muscle or aponeurosis for resection or advancement. This method is particularly advantageous in cases of aponeurotic ptosis where direct visualization is often necessary. Benefits include enhanced control over eyelid height and contour, with the potential for superior cosmetic outcomes due to hidden incisions. However, the anterior approach carries a higher risk of complications such as hematoma, infection, and scarring, necessitating careful patient selection and surgical expertise. Conversely, the posterior approach, involving an internal incision through the conjunctiva, is less invasive and avoids external scars. This technique is predominantly used for mild to moderate ptosis, especially in patients with preserved levator function. It targets Müller's muscle, which is less traumatic and associated with a shorter recovery time and lower complication rates. The posterior approach is favored for its simplicity and reduced risk profile, though it offers limited visualization and may not be suitable for all ptosis types. In conclusion, both the anterior and posterior approaches to eyelid ptosis repair have distinct advantages and limitations. The choice of technique should be individualized, considering factors such as the severity of ptosis, patient anatomy, desired outcomes, and potential risks. A thorough preoperative assessment and discussion of patient expectations are essential to achieving the best surgical results.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
The central nervous system (CNS) and the immune system might cooperate with each other on various levels in a body. Interestingly, signaling pathways linked to several G protein-coupled receptors (GPCRs) have been shown to be involved in the pathology both of CNS disorders including neurodegenerative diseases and/or immune-related diseases. Oxidative stress and inflammation are likely to contribute to cell damage and death in these disorders, which in turn could cause mitochondrial injury. Interestingly, it has been revealed that gut microbiota could play a significant role in changing the phenotype of various neuron and/or immune-related disorders. Remarkably, GPCR signaling has been recognized as a key upstream regulator for autophagy/mitophagy via the action of the mammalian/mechanistic target of rapamycin (mTOR) signaling. In addition, adjusting the composition of gut microbiota could be applied to modulate the autophagy/mitophagy by the alteration of GPCR signaling to ameliorate the mitochondrial injury. Collectively, this approach may contribute to the innovative development of promising therapeutics for neurodegenerative diseases and/or immune-related diseases. This review describes that concept, highlighting the intracellular mTOR signaling from the cell surface GPCRs within cells of Gut-brain-immune axis.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Colorectal cancer (CRC) is one of the most common malignancies worldwide. Advanced CRC has a poor prognosis, with treatment primarily relying on chemotherapy combined with targeted therapies. Currently, immunotherapy based on immune checkpoint inhibitors is reserved exclusively for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, which represent less than 10% of advanced CRC cases. Chimeric antigen receptor (CAR)-T cell therapy is a type of adoptive cell therapy involving modified T-lymphocytes engineered to express chimeric antigen receptors, enabling them to recognize surface antigens expressed by tumor cells. CAR-T cell therapy has demonstrated efficacy in treating hematological malignancies such as lymphoma, myeloma, and leukemia. However, its efficacy in solid tumors remains limited due to several limitations such as antigen heterogeneity, restricted CAR-T cell trafficking into the tumor area, and the presence of an immunosuppressive tumor microenvironment. Developing novel CAR-T cell therapies for solid tumors represents an unmet need, particularly for cases where immune checkpoint blockade is ineffective, such as CRC. Preclinical studies have shown the efficacy of various CAR-T cell models targeting a wide range of tumor-associated antigens in CRC, both in vitro and in vivo. Despite these promising results, the clinical efficacy of CAR-T cell therapy for CRC has been limited in early-phase clinical trials. Factors such as trial design or tumor characteristics, including antigen heterogeneity and the immunosuppressive microenvironment, should be considered. The development of innovative CAR-T cell models and the identification of novel antigens may improve the effectiveness of CAR-T cell therapy for CRC patients.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Immune checkpoint inhibitors are one of the most promising areas in oncoimmunology research. T cell immunoglobulin and mucin domain-3 (TIM-3) expression has been linked to the advanced stages with reduced survival in several types of cancer, primarily due to its association with the dysfunction in T cells. Thus, TIM-3 is an interesting target in designing advanced therapy for cancer. TIM-3 has been implicated in resistance to immunotherapy on account of its involvement in T cell exhaustion. Identifying small molecule inhibitors targeting TIM-3 with high affinity, either alone or in combination with either chemotherapy or other types of immunotherapies could significantly enhance the life span, overcoming the resistance and overall immune response in therapy. TIM-3 pathway is multidimensional in terms of canonical signaling with varied expression of immune cells and diverse ligands and modulates the immune response. This may include restoration of the functioning of killer T lymphocytes and natural killer cells (NK cells) and likely promise better results in cancer immunotherapy. In this review, we will discuss the immunomodulatory role of TIM-3 in cancer, with special emphasis on lymphoma and solid tumors, and their role in diverse immune cells in tumorigenesis and inflammation.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Interleukins (ILs) are a group of cytokines that regulate immune responses and inflammation, playing important roles in the pathogenesis, diagnosis, and treatment of urological diseases. This review provides an analysis of the involvement of interleukins in bladder cancer, benign prostatic hyperplasia (BPH), renal cell carcinoma (RCC), urinary tract infections (UTIs), interstitial cystitis/bladder pain syndrome (IC/BPS), and urolithiasis. ILs regulate immune cell activity and mediate tumor progression, immune evasion, and inflammation, making them valuable biomarkers and therapeutic targets. Elevated levels of IL-6, IL-8, and IL-18 are associated with disease severity and prognosis in bladder cancer, RCC, and BPH. Additionally, IL-10 is anti-inflammatory, offering therapeutic potential in chronic inflammatory conditions such as BPH and IC/BPS. Emerging therapies targeting IL pathways, including IL-2 and IL-17 inhibitors, have shown promise in modulating immune responses and improving clinical outcomes. The diagnostic utility of urinary IL biomarkers, particularly IL-6 and IL-8, has been demonstrated in UTIs and urolithiasis. This review highlights not only the therapeutic potential of interleukins but also their integral role in the immunopathology of urological diseases, distinguishing it from previous analyses by emphasizing IL-targeted therapies to improve diagnostic and therapeutic outcomes.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Glioblastoma is a common primary malignant tumor posing a serious threat to human life and health. Protocatechuic acid (PCA) is a natural phenolic compound with good anti-tumor activity. The study aimed to investigate whether pyroptosis can be activated by PCA in glioma cell.
Methods: Different concentrations of PCA were used to treat glioma cell lines U87 and U251 for varying durations. Cell proliferation was quantified using the Cell Counting Kit-8 (CCK-8) assay. The Transwell chamber assay was employed to evaluate cell invasion, while cell migration was assessed via the scratch assay. Pyroptosis levels were determined through immunofluorescence staining. Additionally, the protein and mRNA expression levels of nucleotide-binding and oligomerization domain-like receptor thermal protein domain-associated protein 3 (NLRP3), cysteinyl aspartate specific proteinase (caspase-1), and gasdermin D (GSDMD) were analyzed using Western blotting and quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
Results: Intervention with PCA resulted in a significant suppression of viability, invasion and migration of glioma cells in a dose-dependent manner (p < 0.05). Additionally, the GSDMD positivity rate, as well as the protein and mRNA expression levels of NLRP3, caspase-1, and GSDMD showed significant increases in glioma cells (p < 0.05). Further intervention with NLRP3-specific inhibitor MCC950 reversed the effects of PCA and resulted in a significant increase in cell viability and number of invading cells (p < 0.01), a significant decrease in GSDMD positivity (p < 0.01), and a significant decrease in the protein and mRNA expression levels of NLRP3, caspase-1, and GSDMD in glioma cells (p < 0.01).
Conclusion: PCA mediates pyroptosis in glioma cells by regulating the NLRP3/caspase-1/GSDMD signaling pathway.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Celastrol has been shown to inhibit hepatocellular carcinoma (HCC) progression, but the underlying mechanism is unknown. Fanconi anemia complementation group D2 (FANCD2), a ferroptosis inhibitor, promotes HCC proliferation and invasion. This study aims to investigate whether Celastrol exerts its effects by targeting FANCD2.
Methods: Using data from The Cancer Genome Atlas (TCGA), we identified differentially expressed genes in HCC utilizing Gene Expression Profiling Interactive Analysis 2 (GEPIA 2). FANCD2 and Celastrol were analyzed for molecular docking using Autodock, which was based on geometric matching and energy matching. The correlation between FANCD2 and survival rate was analyzed using Kaplan-Meier's estimates by log-rank (Mantel-Cox) test. HCC cell lines (SNU-423 and SNU-387) were overexpressed or silenced with FANCD2 and treated with Celastrol. Autophagy and ferroptosis were evaluated by measuring oxidative stress and related markers, and cell function experiments were performed.
Results: High expression of FANCD2 was correlated with poor survival in HCC patients. Celastrol targeted FANCD2, reducing its level in SNU-423 and SNU-387 cells. FANCD2 overexpression resulted in increased SNU-423 cell viability, migration, invasion, and tube formation ability, as well as attenuated autophagy and ferroptosis, while FANCD2 knockdown in SNU-387 cells showed opposite effects. Additionally, FANCD2 overexpression reversed the ability of Celastrol to induce autophagy and ferroptosis and to inhibit SNU-423 cell survival in vitro, while FANCD2 knockdown enhanced the effects of Celastrol in SNU-387 cells.
Conclusion: Celastrol inhibits malignant behavior in HCC cells by targeting FANCD2 to induce autophagy-dependent ferroptosis.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Primary open-angle glaucoma (POAG) is one of the common types of glaucoma, an eye disease that causes irreversible blindness. Fibrosis of the trabecular meshwork (TM) caused by the accumulation of extracellular matrix (ECM) induced by transform growth factor-β (TGF-β) is closely related to high intraocular pressure (IOP). Deacetylase Sirtuin1 (Sirt1) plays an anti-oxidation and anti-fibrosis role in many diseases, including glaucoma; however, its mechanisms have not been fully revealed. In this study, we analyzed the anti-fibrotic role of Sirt1 in TM fibrosis induced by TGF-β to investigate potential mechanisms.
Methods: Transcriptome sequencing of trabecular meshwork cells (TMCs) was performed after transfection with the adenovirus-Sirt1-green fluorescent protein (Adv-Sirt1-GFP). Then, 5 ng/mL TGF-β was used to induce overexpression of ECM in TMCs in vitro. The expression of target proteins was detected by Western blot and immunofluorescence, and cytokine expression was detected by enzyme-linked immunosorbent serologic assay (ELISA). At the same time, we detected the functional changes in cell proliferation, adhesion, and migration.
Results: After treatment with TGF-β, we found that the accumulation of ECM was increased (fibronectin (FN), collagen I (COL I), laminin (LN), p < 0.05), and the phosphorylation (activation) of Smad2/3 and the expression of Smad4 were increased (p < 0.001). The results of transcriptome sequencing suggested that Sirt1 inhibits the expression of ECM by regulating the functions of co-Smad and co-COL binding proteins, thus participating in the regulation of cell adhesion. Finally, we confirmed that: (1) Sirt1 reduced the accumulation of ECM in TMCs by inhibiting the phosphorylation of Smad2/3 (p < 0.05) and the expression of Smad4 (p < 0.05), and (2) Sirt1 decreased the adhesive ability of TMCs by reducing the secretion of integrins (integrin-α3 (ITGα3), p < 0.01; integrin-β1 (ITGβ1), p < 0.001) and cadherins (E-cadherin, p < 0.01; N-cadherin, p < 0.01), and promoted cell migration (p < 0.05).
Conclusion: Sirt1 promotes the migration of cells and reduces the accumulation of ECM in TMCs induced by TGF-β by inhibiting the activation of Smad2/3 and the expression of Smad4.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Common cognitive impairment in the elderly may be aggravated by the anesthetic propofol, whereas the mammalian target of rapamycin protein (mTOR)-brain-derived neurotrophic factor (BDNF) pathway and autophagy regulation play a key role in neuroprotection. In this study, we investigated whether esketamine can improve propofol-induced cognitive impairment in aged rats by affecting these mechanisms and revealed potential new therapeutic strategies.
Methods: A propofol-induced age-related cognitive dysfunction model was used in the experiments. Behaviours were evaluated by the sugar-water preference test and the water maze, neuronal damage by Nissl staining, and neuronal apoptosis was detected by flow cytometry. Neuronal autophagy-related proteins phospho-mammalian target of rapamycin (p-mTOR), mTOR, BDNF, phospho-Unc-51 like autophagy activating kinase 1 (p-ULK1), Unc-51 like autophagy activating kinase 1 (ULK1), autophagy related 5 (ATG-5), and microtubule-associated protein 1 light chain 3-I/microtubule-associated protein 1 light chain 3-II (LC3-II/LC3-Ⅰ) were detected by western blotting (WB); immunohistochemistry was used to detect the deposition of β-amyloid (amyloid-beta, Aβ) in the hippocampal region and the positivity rate of caspase-3; postsynaptic density protein 95 (PSD95) and synapsin I (SYN1) levels were detected by WB.
Results: Water maze and sugar-water preference tests showed that the propofol group had longer escape latency, more platform crossings, lower platform quadrant time ratio, and reduced sugar-water preference, all improved by esketamine (p < 0.05). Nissl staining and immunohistochemistry revealed sparser neurons, darker staining, wrinkled morphology, and increased Aβ in the propofol group, all improved by esketamine (p < 0.05). WB showed increased phosphorylated Tau (p-Tau) and Aβ, higher apoptosis and caspase-3 positivity, and decreased BDNF, and ATG-5 in the propofol group, all reversed by esketamine. Propofol increased inflammatory markers and decreased SYN1, PSD95, and SYN expression, all of which were improved by esketamine (p < 0.05).
Conclusion: By inhibiting the mTOR-BDNF pathway with esketamine, the inhibition of neuronal autophagy ultimately improves the cognitive dysfunction induced by propofol.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: The management of temporomandibular disorders (TMD) remains challenging, with its underlying pathological mechanisms requiring further investigation. This study aimed to explore the effects of Botulinum Toxin A (Botox A) on the lateral pterygoid (LP) muscle and its impact on condylar subchondral bone mass.
Methods: Rats were randomly assigned to either an experimental group (injected with Botox A) or a control group (injected with an equal volume of 0.9% normal saline). All rats were sacrificed at 2-, 4-, 8-, or 12-weeks post-injection. The right condyles were harvested and analyzed using Micro-computed tomography (CT) scanning and hematoxylin-eosin staining to evaluate changes in the condylar subchondral bone. Osteoclast activity in the subchondral bone was assessed via tartrate-resistant acid phosphatase (TRAP) staining. The activities of osteoclasts and osteoblasts in subchondral bone were detected by western blotting.
Results: At 2-weeks post-Botox A injection, the trabecular number (Tb.N) was significantly lower (p < 0.01). At 2- and 4-weeks, bone volume fraction (BV/TV) and trabecular thickness (Tb.Th) were significantly lower (p < 0.05), while trabecular space (Tb.SP) and the ratio of bone surface area to bone volume (BS/BV) were significantly increased in the experimental group compared to control group (p < 0.05). At 8-weeks, BS/BV remained significantly elevated (p < 0.05), but no significant differences were observed in Tb.N, Tb.Th, BV/TV, or Tb.Sp at 8- and 12- weeks. Osteoclast numbers in the condylar subchondral bone were significantly higher in the Botox A group at 2-, 4-, and 8-weeks compared to the control group (p < 0.05). Additionally, protein expression levels of osteocalcin (OCN) and type I collagen (COL1A1) were markedly increased in the experimental group at 8- and 12-weeks (p < 0.05).
Conclusions: Botox A induces a significant reduction in condylar subchondral bone mass in rats during the early post-injection period, with subsequent time-dependent recovery.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Epilepsy is a prevalent neurological disorder characterized by transient brain dysfunction due to abnormal neuronal discharges. Oxidative stress is strongly correlated with epilepsy onset and progression and is a critical factor in triggering seizures. Therefore, antioxidants may serve as effective anti-seizure treatments. Cerium oxide nanoparticles (CNP), which have antioxidant properties and function as nano-enzymes, may offer neuroprotective and therapeutic benefits for epilepsy. This study aims to investigate the effects of CNP on epilepsy.
Methods: We established a pilocarpine (PILO)-induced epilepsy rat model to assess the effects of pretreatment with different doses of CNP on epileptic behavioral changes, electroencephalographic activity, and nuclear factor erythroid 2-related factor 2 (NRF2) signaling in rats.
Results: In brief, a dose of 2.5 mg/kg CNP prolonged the latency of PILO-induced seizures in rats (p < 0.05), reduced the severity of seizures (p < 0.05), and decreased the 24-h mortality rate (p < 0.01). Additionally, CNP also extended the latency of epileptiform discharges (p < 0.01) and significantly decreased the average energy density of electroencephalographic activity (p < 0.0001). It inhibited seizure-induced lipid peroxidation (p < 0.001) and increased superoxide dismutase (p < 0.05) and catalase activities (p < 0.01). Furthermore, pretreatment with CNP elevated the expression of NRF2 and NADPH:quinone oxidoreductase 1 (NQO1) in antioxidative stress pathways (p < 0.05) and reduced neuronal necrosis and degeneration in CA1 and CA3 regions (p < 0.05).
Conclusions: CNP exhibits anti-epileptic and neuroprotective effects in PILO-induced epilepsy. This protective effect is likely due to the enhancement of the NRF2 signaling pathway, which regulates antioxidant enzymes, improves neuronal defense mechanisms against oxidative stress, and reduces seizure-induced neuronal damage.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Chordoma is a rare, primary malignant bone tumor arising from remnants of embryonic notochord tissue. While the long non-coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1) has been implicated in various cancers, its role in chordoma remains to be elucidated. This study aims to elucidate the mechanisms by which lncRNA NEAT1 influences chordoma growth and apoptosis.
Method: lncRNA NEAT1 expression was assessed in chordoma using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Two chordoma cell lines with high lncRNA NEAT1 expression were selected for lncRNA NEAT1 knockdown and inhibitor of apoptosis-stimulating protein of p53 (iASPP) overexpression experiments. Cell survival was assessed using Cell Counting Kit-8 (CCK-8) and colony formation assays, while apoptosis and iASPP expression levels were analyzed by flow cytometry, Western blotting (WB), and RT-qPCR. In vivo, treated U-CH1 cell lines were subcutaneously injected into nude mice to establish a chordoma model. Tumor apoptosis was evaluated through hematoxylin-eosin (HE) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay and WB was used to measure the levels of apoptosis-related proteins and iASPP in the tissues.
Results: The lncRNA NEAT1 was highly expressed in chordoma. Silencing lncRNA NEAT1 inhibited the survival and proliferation of chordoma cell lines MUG-Chor1 and U-CH1, and promoted apoptosis (p < 0.05). Overexpression of iASPP counteracted these effects, enhanced cell growth and inhibited apoptosis in the si-lncRNA NEAT1 group (p < 0.05). HE and TUNEL staining results indicated that silencing lncRNA NEAT1 reduced cell proliferation and division in chordoma tissues, and led to a marked increase in apoptosis (p < 0.05). These effects were reversed by overexpression of iASPP (p < 0.05).
Conclusion: In chordoma, lncRNA NEAT1 is highly expressed, and silencing lncRNA NEAT1 inhibits the proliferation and induces apoptosis of chordoma cells while decreasing the expression of iASPP. These findings offer new insights into the involvement of the lncRNA NEAT1/iASPP pathway in chordoma development.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Polyubiquitin gene Ubb knockout (KO) mice exhibit early onset reactive astrogliosis and adult-onset hypothalamic neurodegeneration with obesity. However, it remains unknown why the obesity phenotype only manifests in adulthood and why mice are smaller at an early age. Therefore, this study aimed to identify the link between neuroinflammation at an early age and adult-onset leptin signaling dysfunction in Ubb KO mice.
Methods: To investigate neuroinflammatory marker expression in the hypothalamus of Ubb KO mice, RNA-seq analysis and quantitative reverse transcription-polymerase chain reaction were used. Moreover, astrocytes isolated from postnatal brains were cultured and pure astrocytes were obtained by magnetic-activated cell sorting. Furthermore, mice were challenged with lipopolysaccharide (LPS) to induce upregulation of neuroinflammatory markers, including lipocalin-2 (LCN2). Leptin signaling was examined through the administration of leptin via intraperitoneal or intracerebroventricular injection, followed by monitoring of relevant proteins using immunofluorescence and western blot analyses.
Results: In Ubb KO mice, reactive astrogliosis occurred at an early age and increased the expression of Lcn2 and other neuroinflammatory markers. Upon exposure to LPS, these levels showed upward trends; however, they were comparable with those in wild-type mice, suggesting that Ubb KO mice were under intrinsic inflammatory stress. In adulthood, leptin signaling dysfunction was observed owing to elevated levels of negative regulators, such as suppressor of cytokine signaling-3 (SOCS3) and forkhead box protein O1 (FOXO1), possibly as a result of chronic neuroinflammation.
Conclusion: This study demonstrates that Lcn2 expression is increased in young Ubb KO mice. Although leptin signaling is intact at an early age, high LCN2 levels may contribute to reduced daily food intake and lower body weight. Chronic neuroinflammation resulting from reactive astrogliosis persists into adulthood, leading to leptin signaling dysfunction. This is most likely a result of elevated levels of SOCS3 and FOXO1, both of which are negative regulators of leptin signaling.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Glycolytic metabolism has been identified as a facilitator of tumor cell proliferation. Therefore, this study aims to investigate the mechanisms by which the sperm-associated antigen 4 (SPAG4)/cellular myelocytomatosis oncogene (c-Myc)/sulfotransferase 2B1 (SULT2B1) axis regulates glycolytic metabolism and influences the viability of HT29 cells.
Methods: SPAG4, c-Myc, and SULT2B1 levels were assessed in HT29 cells using Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot analyses. Moreover, overexpression and knockdown in HT29 cell models were successfully established. Furthermore, cell viability and proliferation were evaluated using Cell Counting Kit-8 (CCK-8) and colony formation assays. Various key parameters such as glucose uptake, lactate production, Adenosine Triphosphate (ATP)/Adenosine Diphosphate (ADP) ratio, and the expression levels of Glucose transporter 1 (GLUT1) and Lactate dehydrogenase A (LDHA) were determined to examine glycolytic metabolism. Additionally, the relationship between SPAG4, c-Myc, SULT2B1, and glycolysis was assessed using the immunofluorescence staining approach and 2-Deoxy-D-glucose (2-DG) therapy.
Results: The expression levels of SPAG4, c-Myc, and SULT2B1 were significantly elevated in HT29 cells (p < 0.05). Moreover, silencing SPAG4 and c-Myc substantially reduced glycolytic metabolism and suppressed HT29 cell viability and colony formation capability (p < 0.05). Additionally, elevated SULT2B1 expression effectively counteracted the glycolytic reduction induced by silencing SPAG4 and c-Myc, enhancing cellular viability and colony formation capability (p < 0.05).
Conclusions: In summary, SPAG4 knockdown effectively suppresses HT29 cell proliferation and colony formation ability by decreasing SULT2B1 expression through the downregulation of c-Myc, leading to the reduction of glycolytic metabolism.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: Obesity threatens human health, and interventions to reduce obesity may have important effects on the gut microbiota. This study investigated alterations in gut microbial composition in response to aerobic exercise (AE) and intermittent fasting (IF).
Methods: We randomly divided mice into four groups of seven mice each: normal, obesity, exercise, and fasting. The normal group was fed a Chow Diet, whereas the other three groups were fed a High Fat Diet (HFD). After 13 weeks, the exercise group was subjected to aerobic treadmill running, and the fasting group started IF for 8 weeks. We then analyzed the composition of the fecal microbiome in all mice at the end of 21 weeks.
Results: Our investigation revealed that the HFD significantly influenced species (s)_Romboutsia ilealis, genus (g)_Dubosiella, and g_Blautia. AE predominantly affected family (f)_Rhizobiaceae and g_Rikenella, indicating its impact on enhancing microbial taxa associated with improved metabolic health profiles. On the other hand, IF prominently altered the abundance of s_Lactobacillus johnsonii and g_Colidextribacter, which are known for their roles in enhancing glucolipid metabolism and anti-inflammatory activity. Furthermore, the exercise group displayed increased diversity within f_Rhizobiaceae, potentially associated with anti-inflammatory benefits. The IF intervention was particularly effective in enriching s_Lactobacillus johnsonii, suggesting its pivotal role in regulating metabolic responses influenced by fasting.
Conclusion: The results demonstrated significant beneficial alterations in microbial composition following AE and IF interventions, which supports the use of personalized approaches for obesity management and overall health.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Objective: This study aimed to investigate the effects of curcumin (Cur) on programmed cell death 1 ligand 1 (PD-L1) expression in neutrophils from septic rats and its regulatory influence on T-lymphocyte apoptosis and lung injury in a rat sepsis model.
Methods: Cecum ligation and puncture (CLP) experiments were conducted to establish a rat sepsis model, with the subsequent grouping of rats based on curcumin administration. Rats were monitored for 7 days to assess the 7-day survival rate. Serum, lung tissues, and thymus tissues were collected. Flow cytometry and immunohistochemistry were utilized to assess the number of PD-L1-positive neutrophils and PD-L1 positivity in both blood and lung tissues. Hematoxylin and eosin (HE) staining and Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) histochemistry were employed to examine pathological changes and cell apoptosis in lung and thymus tissues. Furthermore, a kit was employed to measure the activity of myeloperoxidase (MPO), a marker of neutrophil activation, in lung tissues. Enzyme-linked immunosorbent assay (ELISA) was utilized to determine plasma levels of inflammatory factors. Neutrophils were extracted and co-cultured with normal T lymphocytes. TUNEL assays were used to evaluate T-lymphocyte apoptosis, and Western blotting was performed to analyze the expression of PD-L1 and programmed cell death 1 (PD-1).
Results: In in vivo experiments, septic rats exhibited a markedly low 7-day survival rate of 12.5%, significantly elevated PD-L1 expression and positivity in blood and lung tissues, severe lung and thymus tissue damage, and significant cell apoptosis. Additionally, they had increased plasma concentrations of tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6), and decreased plasma concentration of interleukin 10 (IL-10) compared to normal and sham-operated rats (p < 0.05). Curcumin-treated septic rats demonstrated significantly improved 7-day survival, reduced PD-L1 expression and positivity in blood and lung tissues, mitigated lung and thymus tissue injury and cell apoptosis, lower plasma concentrations of TNF-α and IL-6, and higher plasma concentrations of IL-10 (p < 0.05). In vitro experiments showed that co-culture of T lymphocytes with neutrophils from septic rats resulted in a significantly higher rate of T cell apoptosis and increased expression of PD-L1 and PD-1 compared to co-culture with neutrophils from sham-operated rats (p < 0.05). Neutrophils from curcumin-treated rats exhibited a significantly lower rate of apoptosis in co-cultured T lymphocytes and decreased expression of PD-L1 and PD-1 (p < 0.05). The addition of PD-L1 antibodies to co-cultured neutrophils and T lymphocytes in septic rats significantly reduced T lymphocyte mortality (p < 0.05).
Conclusion: Curcumin effectively mitigates lung and thymus injury during sepsis and attenuates the apoptosis of rat T lymphocytes by down-regulating PD-L1 expression in centrocytes, both in vivo and in vitro.
Abstract (
)
Download PDF (
)
HTML
(
)
Knowledge map
Save
Background: The incidence of atrial fibrillation (AF) presents a markedly increasing trend with advancing age. Thus, with the growing population of elderly individuals, AF has emerged as a significant medical and socioeconomic problem. The objective of this study was to investigate the correlation of mitogen-activated protein kinase 10P (MAPK10P) gene polymorphism with P-wave peak time (Pwd) and P-wave dispersion (Pmax) among elderly individuals with paroxysmal AF.
Methods: From January 2021 to October 2022, 125 elderly patients with essential hypertension were recruited for research in our Cardiology Department. According to the European Society of Cardiology (ESC) Atrial Fibrillation Management Guidelines, 53 patients with ≥2 documented paroxysmal AF episodes in the previous year were classified as the observation group, while 72 patients without AF formed the control group. Patient data were collected, and a 12-lead electrocardiogram was used to measure Pwd and Pmax. MAPK10P genotype was identified using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The association between MAPK10P genotype and AF risk, as well as the impact of different genotypes on Pwd and Pmax parameters, were evaluated.
Results: The baseline characteristics did not show any significant difference between the two groups (p > 0.05). The values of Pwd and Pmax in the observation group were significantly greater than those in the control group (p < 0.05). The occurrence rate of the CC genotype was lower in the observation group than in the control group (p < 0.05), while the occurrence rates of the CG and GG genotypes were higher in the observation group than in the control group (p < 0.05). Additionally, the frequency of the G allele was higher in the observation group than in the control group (p < 0.05). AF patients with the CG+GG genotype exhibited higher Pwd and Pmax values compared to those with the CC genotype (p < 0.05). Patients without AF who had the CG+GG genotype had higher Pwd and Pmax values compared to those with the CC genotype (p < 0.05).
Conclusion: In elderly patients, the presence of the G allele in the MAPK10P gene polymorphism is linked to an increased risk of AF, as well as Pwd and Pmax. This study provides valuable insights into the potential role of MAPK10P gene variations in influencing P-wave characteristics during the development of paroxysmal AF in elderly patients.
